{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Cancer+%28Mcrc%29", "query": { "condition": "Metastatic Colorectal Cancer (Mcrc)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 86, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Cancer+%28Mcrc%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T21:15:52.066Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03890731", "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Cancer" ], "interventions": [ { "name": "BAY73-4506 (Regorafenib, Stivarga)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-04-02", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03890731" }, { "nct_id": "NCT04607668", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer Metastatic", "Myelosuppression-Adult", "Chemotherapeutic Toxicity" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2021-01-06", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 24, "location_summary": "Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04607668" }, { "nct_id": "NCT07222800", "title": "Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Neoplasms by Site", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Rectal Diseases", "Colorectal Neoplasms" ], "interventions": [ { "name": "PF-08634404", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2025-12-11", "completion_date": "2031-08-01", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 150, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 124 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222800" }, { "nct_id": "NCT04108481", "title": "Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer Metastatic", "Colon Cancer", "Metastatic Colorectal Cancer", "Rectal Cancer", "Liver Metastasis Colon Cancer", "Colo-rectal Cancer", "Colorectal Adenocarcinoma", "Colorectal Neoplasms", "Liver Metastases", "Colorectal Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Yttrium-90 RadioEmbolization", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2020-10-05", "completion_date": "2023-11-17", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04108481" }, { "nct_id": "NCT03563157", "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic", "mCRC" ], "interventions": [ { "name": "Aldoxorubicin Hydrochloride", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-09-28", "completion_date": "2019-08-21", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563157" }, { "nct_id": "NCT01931150", "title": "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cetuximab-induced Papulopustular (Acneiform) Rash Who Have", "Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Topical Dapsone 5% Gel", "type": "DRUG" }, { "name": "Moisturizer", "type": "OTHER" }, { "name": "oral antibiotics", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931150" }, { "nct_id": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "zanidatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 768, "start_date": "2024-06-03", "completion_date": "2029-01-08", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Cerritos, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06324357" }, { "nct_id": "NCT01507545", "title": "Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "MORAb-004", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best supportive care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2012-03-27", "completion_date": "2013-10-20", "has_results": true, "last_update_posted_date": "2022-05-06", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 67, "location_summary": "Alhambra, California • Bakersfield, California • Burbank, California + 54 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01507545" }, { "nct_id": "NCT00561470", "title": "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)", "type": "DRUG" }, { "name": "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1226, "start_date": "2007-11", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2012-09-28", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561470" }, { "nct_id": "NCT02205398", "title": "Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck (SCCHN)", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "INC280", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2014-07-28", "completion_date": "2017-01-20", "has_results": false, "last_update_posted_date": "2019-01-22", "last_synced_at": "2026-06-25T21:15:52.066Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Salt Lake City, Utah", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02205398" } ] }